Why has the United States handled this pandemic so badly? The Editors note that although we came into this crisis with enormous advantages, our current political leaders have demonstrated that they are dangerously incompetent.

Proud to share our subanalysis from TOPCAT study regarding depression in patients with HFpEF #JACCHF #HFpEF #depression. https://t.co/px4eMFJhe1

Fantastic work by @singh_kavisha which showcased the role of simulation in assessment of cardiology fellow performance in TTE scanning that's especially relevant in the COVID-19 era. @UTSWCardfellow https://t.co/RwR5syzKAp

The cholesterol story is never simple. Our work on multi ethnic cohorts from the US/Europe to see how HDL particles a/w vascular events and how that compares to HDL-C with @dranandrohatgi @AlvinChandraMD @DrPJoshi @dramitkhera @utswheart & others.

Special Report: RAAS Inhibitors in Patients with Covid-19. #COVID19 #SARSCoV2

So proud to share this @JAMACardio article written by my friend and colleague Dr. Riccardo Inciardi who's at the front line fighting #COVID19 in Italy. Also featured @nytimes. Thank you for sharing your valuable experience! https://t.co/brqIdHhD4W https://t.co/KmEuaNHErw

Striking data in @ESC_Journals #EJHF by @PeterMoliner: How do pts with HFrEF die? The answer appears to be changing if asked in 2001 vs 2018. Reflects treatment successes & new challenges! Our accompanying editorial @RBPatelMD #AnjuNohria @JavedButler1 https://t.co/DFBGbBNLIE

📍Health-Related Quality of Life in HFpEF: PARAGON-HF Trial (compared with PARADIGM trial) 📌 HRQL was largely worse in women and was similar in HFpEF and HFrEF @JACCJournals @secardiologia @SACardiologia https://t.co/ED3HzBrnFf

Congrats @mvaduganathan @Hirji1987 for leading this study and thanks to all the coauthors for their help and contribution @AqamarMD @bajaj_nav @AnkurGuptaMD @CardioOncology @JavedButler1 @AlvinChandraMD Bonnie Ky, Mark Haykowsky, @vgzmd, anju nohria @UTSWNews @UTSWCardfellow

Long-awaited #PROVEHF did not disappoint 🙌🏻: -Rapid (<2w) and large reduction in NT-proBNP (at lowest #entresto dose) -Sign reverse remodelling (LVEF +9% and LVMi -16 g/m2) -Consistent in RASi-naive; low NP and non-target dose CONGRATULATIONS @JJheart_doc @scottdsolomon

Potential intriguing implications from the "neutral" #PARAGON_HF trial. Patients with lower LVEF may have benefits similar to #PARADIGM_HF #ESCCongress

Rockstars in cardiology @escardio 2019 @scottdsolomon #PARAGON_HF #DAPA_HF #ESCcongress

Dapagliflozin home run for patients!

#PARAGONHF p=0.058 for primary endpoint: HR 0.87 (0.75-1.01) 👁Super interesting sex differences: HR 0.73 (0.59-0.90) in 👩🏻‍🦳 and 1.03 (0.85-1.25) in👨🏻‍🦳 👁Signal of better treatment effect with lower EF Let the debate begin! https://t.co/quU5zviG0q @Novartis @scottdsolomon

A paper we published a year ago closely related to our recent JACC HF #QOL in #HFpEF paper. @scottdsolomon

It's like I'm rounding again with @MarkDrazner in the halls of old St. Paul Hospital. Thank you. @UTSWCardfellow

Thanks @mvaduganathan for sharing this! Proud to see our work with @scottdsolomon published

Happy to share our findings published at #JACC from the #DallasHeartStudy regarding the association of temporal changes in body fat distribution and #hypertension